The global GLP-1 receptor agonist market is poised for remarkable expansion in the coming decade, according to a recent market analysis. Projections suggest an impressive surge from US$ 23,854.53 ...

Research is highlighting how GLP-1 is expressed in prostate cancer, suggesting that GLP-1 agonists might have a future role in the management of this cancer.

Researchers at the University of Toronto have found naturally occurring compounds in the gut that can be harnessed to reduce inflammation and other symptoms of digestive issues.

Gregory Petsko of Brigham and Women’s Hospital in Boston had a different interpretation. Since tau is not an integral membrane protein, he thinks that SORL1 must meet tau at the cell surface where the ...

Amgen enjoyed its biggest one-day stock gain since 2009 after top executives delivered positive comments about its obesity candidate MariTide.

Glucagon-like peptide 1 (GLP1) receptor agonist use does not appear to be associated with an increased risk for thyroid ...

Its End-to-End Platform is built on multiple proprietary and exclusive technologies that enable the Company to generate optimal T cell receptors against both cancer testis antigens and neoantigens, ...

Angle signs commercial agreement with Large Pharma to develop Parsortix-based androgen receptor: Gildford, England Saturday, May 4, 2024, 12:00 Hrs [IST] Angle plc, a world-leadin ...

Treatment with DD01 treatment reduced hepatic steatosis by more than 50% in 4 weeks, according to phase 1 data. The Food and Drug Administration (FDA) has granted Fast Track designation to DD01 for ...

A recent study suggests that people with a rare condition known as growth hormone receptor deficiency (GHRD), also called ...

During a Case-Based Roundtable® event, Ruth M. O'Regan, MD, led a discussion on whether to order next-generation sequencing and/or circulating tumor DNA testing for a patient with hormone ...

Semaglutide showed significant improvements in KCCQ-CSS score and reduction in body weight compared to placebo. 2. There were fewer serious adverse events in the semaglutide group. Evidence Rating ...